Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
June 25, 2021 09:15 ET
|
FibroGen, Inc
TOKYO, June 25, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen")...
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
June 17, 2021 07:00 ET
|
FibroGen, Inc
FibroGen Exclusively Licenses HiFiBiO’s Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 ProgramsTransformative Transaction for FibroGen’s Early-stage Pipeline HiFiBiO to...
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
June 16, 2021 08:00 ET
|
FibroGen, Inc
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...
FibroGen to Present at Upcoming Investor Conferences
May 27, 2021 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen Reports First Quarter 2021 Financial Results
May 10, 2021 16:01 ET
|
FibroGen, Inc
Roxadustat net product revenue in China of $15.4 million, on a US GAAP basis Total roxadustat net sales in China of $43.5 million1 by FibroGen and the distribution entity jointly owned by FibroGen and...
FibroGen to Report First Quarter 2021 Financial Results
May 03, 2021 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close. FibroGen will also...
FibroGen to Present at Upcoming Investor Conference
April 28, 2021 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities...
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
April 15, 2021 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, April 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for...
FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
April 12, 2021 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, April 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s...
FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021
April 06, 2021 19:50 ET
|
FibroGen, Inc
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively...